The University of Minnesota is currently seeking newly diagnosed T1D’s to participate in three different trials. If you or a loved one has been diagnosed recently, these studies may be worth exploring. To learn more or inquire about participation, contact: PEDS-DIABETES@UMN.EDU
The TADPOL study is investigating whether an oral medication called DFMO (difluoromethylornithine) can help preserve beta-cell function in people newly diagnosed with T1D. This Phase 2 trial is open to participants ages 4 to 40 who are within 100 days of diagnosis and have normal hearing. DFMO has shown potential in other autoimmune conditions, and researchers are exploring what it can do for those newly diagnosed with T1D.
The COUR study is a Phase 1 trial focused on safety. CNP-103, nanoparticle IV, is a groundbreaking disease-modifying approach which encapsulates 4 recombinant proteins that cover more than 95% of the antigens that drive T1D. Participants must be between 12 and 35 years old, weigh at least 50 kg, and be within 180 days of diagnosis.
WAVE T1D is a Phase 1/2 trial evaluating a multi-drug strategy: ATG (an IV immunotherapy) followed by either adalimumab (a subcutaneous anti-inflammatory) or verapamil (an oral calcium channel blocker). The goal is to assess the safety and efficacy of the therapy combinations in preserving insulin secretion 2 years from randomization in persons with recent-onset stage 3 T1D. Eligible participants are ages 9 to 21, within six months of diagnosis, and weigh more than 30 kg.